ImmunoGenesis to present IMGS-203 preclinical data at SITC 2026
Biotech company ImmunoGenesis will report preclinical progress for its STING-agonist IMGS-203, aimed at treating recurrent glioblastoma, at the SITC 2026 conference.
ImmunoGenesis is scheduled to present preclinical data regarding IMGS-203, a STING agonist candidate, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Phoenix, Arizona. The data focus on the company's progress toward filing for first-in-human clinical trials for patients with recurrent glioblastoma.
Dr. Akash Boda of ImmunoGenesis will deliver both a poster presentation on November 6 and a rapid oral presentation on November 7. The findings detail the investigative work conducted to meet regulatory requirements for clinical testing of the compound.
Glioblastoma remains one of the most difficult cancer types to treat, characterized by aggressive growth and a lack of effective therapeutic options. ImmunoGenesis is attempting to address this through a portfolio of immunotherapies designed to overcome immune resistance in tumors.